Prostanoids for critical limb ischaemia
- PMID: 20091595
- DOI: 10.1002/14651858.CD006544.pub2
Prostanoids for critical limb ischaemia
Update in
-
Prostanoids for critical limb ischaemia.Cochrane Database Syst Rev. 2018 Jan 10;1(1):CD006544. doi: 10.1002/14651858.CD006544.pub3. Cochrane Database Syst Rev. 2018. PMID: 29318581 Free PMC article.
Abstract
Background: Peripheral arterial occlusive disease (PAOD) is a common cause of morbidity and mortality due to cardiovascular diseases in the general population. While numerous treatments have been adopted for different disease stages, there is no option other than amputation for patients presenting with critical limb ischaemia (CLI), unsuitable for rescue or reconstructive intervention.
Objectives: To determine the effectiveness and safety of prostanoids in patients presenting with CLI.
Search strategy: The Cochrane Peripheral Vascular Diseases Group searched their trials register (last searched October 2009) and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (last searched 2009, Issue 4) for publications describing randomised controlled trials (RCTs) of prostanoids for CLI. We ran additional searches in MEDLINE, EMBASE, LILACS, and SciSearch, and we also contacted pharmaceutical companies and experts, in order to identify unpublished data and trials still underway.
Selection criteria: Randomised controlled trials describing efficacy and safety of prostanoids compared with placebo or other pharmacological control treatments, in patients presenting with CLI, without chance of rescue or reconstructive intervention.
Data collection and analysis: Two authors independently selected trials, assessed trials for eligibility and methodological quality, and extracted data. Disagreements were resolved by consensus or by the third author.
Main results: We retrieved 532 citations which after the first screening resulted in 111 potential studies. Finally, after exclusion of studies of poor quality and a lack of sufficient information, 20 trials were included in the review.Prostanoids seem to have efficacy regarding rest-pain relief (risk ratio (RR) 1.32, 95% confidence interval (CI) 1.10 to 1.57; P = 0.003), and ulcer healing (RR 1.54, 95% CI 1.22 to 1.96). Iloprost also shows favourable results regarding major amputations (RR 0.69, 95% CI 0.52 to 0.93). The more frequently reported adverse events when using prostanoids were headache, facial flushing, nausea, vomiting and diarrhoea.
Authors' conclusions: Despite some positive results regarding rest-pain relief, ulcer healing and amputations, there is no conclusive evidence based on this meta-analysis of the long-term effectiveness and safety of different prostanoids in patients with CLI. Further well-conducted, high quality randomised double-blinded trials should be performed.
Similar articles
-
Prostanoids for critical limb ischaemia.Cochrane Database Syst Rev. 2018 Jan 10;1(1):CD006544. doi: 10.1002/14651858.CD006544.pub3. Cochrane Database Syst Rev. 2018. PMID: 29318581 Free PMC article.
-
Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to non-reconstructable peripheral arterial disease.Cochrane Database Syst Rev. 2018 Apr 16;4(4):CD009366. doi: 10.1002/14651858.CD009366.pub2. Cochrane Database Syst Rev. 2018. PMID: 29658630 Free PMC article.
-
Pharmacological treatment for Buerger's disease.Cochrane Database Syst Rev. 2016 Mar 11;3(3):CD011033. doi: 10.1002/14651858.CD011033.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 May 4;5:CD011033. doi: 10.1002/14651858.CD011033.pub4. PMID: 26967103 Free PMC article. Updated.
-
Pharmacological treatment for Buerger's disease.Cochrane Database Syst Rev. 2016 Feb 1;2:CD011033. doi: 10.1002/14651858.CD011033.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2016 Mar 11;3:CD011033. doi: 10.1002/14651858.CD011033.pub3. PMID: 26828199 Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
Cited by
-
Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee.J Atheroscler Thromb. 2020 Aug 1;27(8):809-907. doi: 10.5551/jat.53660. Epub 2020 Jul 4. J Atheroscler Thromb. 2020. PMID: 32624554 Free PMC article.
-
A Thermoresponsive Chitosan/β-Glycerophosphate Hydrogel for Minimally Invasive Treatment of Critical Limb Ischaemia.Polymers (Basel). 2021 Oct 16;13(20):3568. doi: 10.3390/polym13203568. Polymers (Basel). 2021. PMID: 34685327 Free PMC article.
-
Vascular Regeneration in Peripheral Artery Disease.Arterioscler Thromb Vasc Biol. 2020 Jul;40(7):1627-1634. doi: 10.1161/ATVBAHA.120.312862. Epub 2020 May 21. Arterioscler Thromb Vasc Biol. 2020. PMID: 32434408 Free PMC article. Review.
-
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2017 Mar 21;135(12):e686-e725. doi: 10.1161/CIR.0000000000000470. Epub 2016 Nov 13. Circulation. 2017. PMID: 27840332 Free PMC article. Review.
-
Prostacyclin-producing human mesenchymal cells target H19 lncRNA to augment endogenous progenitor function in hindlimb ischaemia.Nat Commun. 2016 Apr 15;7:11276. doi: 10.1038/ncomms11276. Nat Commun. 2016. PMID: 27080438 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous